A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.
Chelsie Derman
Advertisement
Chelsie Derman is an associate editor for HCPLive who covers allergy and psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at [email protected].
Articles by Chelsie Derman
Phase 2 data from AAAAI 2025 shows peanut oral immunotherapy boosts desensitization in children with high-threshold peanut allergy, enabling safe meal-size peanut consumption.
Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.
A Johns Hopkins study presented at AAAAI 2025 found omalizumab was more effective than oral immunotherapy for food allergies, with fewer dropouts due to adverse events.
Climate change is increasing pollen and tick-related allergies, said Scott Commins, MD, PhD, at AAAAI 2025.
A study found that oral physiological changes from allergen exposure in Oral Allergy Syndrome do not alter Anaphylm’s pharmacokinetic or pharmacodynamic profiles.
At AAAAI 2025, HCPLive spoke with Mahdavinia about how climate change impacts allergies.
HCPLive spoke with Cohen about how patients with a peanut allergy responded to oral immunotherapy with autoclaved peanuts.
HCPLive spoke with Nyenhuis at AAAAI 2025 about ways to help patients with allergies despite the growing pollen seasons.
HCPLive spoke with Warren at AAAAI 2025 about a pilot study showing allergen-free food subscriptions reduced healthcare use but lacked significance.
Stallergenes Greer announced that Palforzia is now available for children under 4 years old with a peanut allergy, which follows the extended indication approval in July 2024.
A study at AAAAI 2025 found that dupilumab led to a 73.5% reduction in IgE levels at 24 months.
A study at AAAAI 2025 found that monitoring transepidermal water loss during oral food challenges reduced anaphylaxis rates and epinephrine use in children.
A study suggests the prevalence of Legionella may explain why children with seasonal allergic rhinitis vs perennial allergic rhinitis have more severe symptoms.
Teva and Medincell announced FDA acceptance of their sNDA for UZEDY, a risperidone extended-release injectable, to treat adults with bipolar I disorder.
Mepolizumab led to greater symptom score improvements than omalizumab in severe CRSwNP, though both biologics showed significant nasal polyp reduction.
A new study presented at AAAAI 2025 linked pediatric obesity to a greater risk of developing allergic rhinitis, with a 1.24x increased risk at 1 year.
Phase 3 ANCHOR-1/2 data support depemokimab as a twice-yearly treatment for CRSwNP, effectively reducing blood eosinophil counts over 52 weeks.
A real-world analysis found mepolizumab significantly improved symptoms in CRSwNP patients, reducing SNOT-22 scores, oral corticosteroid use, and surgery rates.
Ahead of AAAAI 2025, HCPLive spoke with Jaroenpuntaruk about varying hypersensitivity reactions in patients with atopic diseases on biologics.
FDA approves expanded use of buprenorphine extended-release injection for opioid use disorder, adding new injection sites and reducing treatment induction time.
Five years after peanut oral immunotherapy, children showed lower allergen-specific IgE and greater IgG4 levels than placebo, indicating sustained immune tolerance.
Phase 3 WAYPOINT trial shows tezepelumab significantly reduces nasal polyp severity, congestion, and surgery needed in severe chronic rhinosinusitis with nasal polyp.
A meta-analysis found oral immunotherapy improves health-related quality of life post-food allergy treatment, but benefits during treatment remain unclear.
A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.
A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.
A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.
A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.
A study found a 6-injection subcutaneous immunotherapy, Grass MATA MPL improves rhinitis quality of life by 27.7% and stimulates broad immune responses.
Advertisement
Advertisement
Advertisement